Arovella Therapeutics (ALA) H1 2026 earnings summary

Executive summary

• Loss from continuing operations increased 29% year-over-year to $1,878,707 for the half-year ended 31 December 2025.

• Revenue and other income decreased 2% year-over-year to $3,624,499.

• Cash at bank as of 31 December 2025 was $19,366,833, down from $20,877,185 at 30 June 2025.

• IND-enabling activities for lead asset ALA-101 completed and IND filed with the U.S. FDA; post-period, IND accepted, enabling first-in-human clinical studies.

• Advanced CLDN18.2-targeting CAR program, demonstrating strong activity against pancreatic cancer cells.

Financial highlights

• Revenue and other income: $3,624,499, down 2% year-over-year.

• Loss from continuing operations: $1,878,707, up 29% year-over-year.

• Net tangible assets per share: 1.57 cents, down from 1.69 cents at 31 December 2024.

• R&D tax incentive income recognized: $3,208,888.

• No dividends paid or declared for the period.

Outlook and guidance

• Company is fully funded to complete Phase 1 clinical trial for ALA-101.

• Focus remains on advancing ALA-101 into clinical trials and expanding the CAR-iNKT platform for solid tumors.